What outcome after the prescription of neoadjuvant chemotherapy in lung cancer?

Boudaya, Mohamed Sadok; Smadhi, H.; Marghli, A.; Charmiti, Fatma; Ouerghi, S.; Mohamed, Jalel; Brahem, Emna; Smati, B.; Mestiri, Taher; Kilani, T.

doi:10.1177/0218492312462576

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with NSCLC in stage IIB/IIIA generally have unfavorable prognosis [ 3 ]. The neoadjuvant chemotherapy (NAC) prior to surgery has been reported to shrink and reduce the primary tumor and distant micro-metastases, thereby reducing the high relapses rates [ 4 ]. In our previous study, platinum-based NAC was demonstrated to significantly increase disease-free survival (DFS) time for patients with stage IIB-IIIA central disease [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

CMTM1_v17 is associated with chemotherapy resistance and poor prognosis in non-small cell lung cancer

Zhang

Tian

et al. 2017

World J Surg Onc

View full text Add to dashboard Cite

BackgroundConsidering neoadjuvant chemotherapy (NAC) prior to surgery could shrink and reduce the primary tumor and distant micro-metastases to reduce the high relapses rates, NAC has been an accepted therapeutic management for patients with non-small cell lung cancer (NSCLC). CMTM1_v17 is highly expressed in human testis tissues and solid tumor tissues but relatively low expression was obtained in the corresponding normal tissues. This study aims to investigate the significance of CMTM1_v17 in NSCLC and its association with platinum-based NAC efficacy.Methods31 pairs of tumor tissues before and after NAC and 78 resected tumor tissues after NAC were utilized for immunohistochemistry (IHC) staining of CMTM1_v17 protein. The correlation between CMTM1_v17 expression and chemotherapy efficacy was analyzed. The prognostic value of CMTM1_v17 index for disease-free survival (DFS) and overall survival (OS) was analyzed using Kaplan-Meier survival and multivariable Cox regression.ResultsCMTM1_v17 expression was related to treatment effect and outcome in tumor tissues after NAC not before NAC from 31 cases of NSCLC. We identified that high CMTM1_v17 expression was associated with low objective remission rate (ORR) (P = 0.008) and poor prognosis (the median OS: 35.1 months vs 65.6 months, P = 0.0045; the median DFS: 17.27 months vs 35.54 months, P = 0.0207) in the 31 patients. Next, we detected CMTM1_v17 expression to confirm correlation between this protein status and clinical characteristics in 78 NSCLC patients with NAC treatment. The upregulation of CMTM1_v17 had a higher SD rate (P = 0.007) and worse outcome (the median OS: 41.0 months vs 80.6 months, P = 0.0028; the median DFS: 33.4 vs 64.8 months, P = 0.0032). COX multivariate analysis indicated that CMTM1_v17 is an independent prognostic risk factor on patients who have received NAC (OS: HR = 3.642, P = 0.002; DFS:HR = 3.094, P = 0.002).ConclusionsCMTM1_v17 expression is significantly associated with chemoresistance and poor prognosis of the early stage NSCLC patients who have received NAC.

show abstract

Section: Introductionmentioning

confidence: 99%